Nemifitide diTFA (INN 00835 diTFA) | Antidepressant

Cas No.:	204992-09-6
Chemical Name:	Nemifitide diTFA
Synonyms:	INN 00835;Netamiftide;Nemifitide diTFA
SMILES:	N/C(=N/CCC[C@H](NC([C@@H]1C[C@@H](O)CN1C([C@H](CC1C=CC(F)=CC=1)N)=O)=O)C(NCC(N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N)=O)=O)/N.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O
Formula:	C₃₃H₄₃N₁₀O₆F^.₂[C₂Ho₂F₃]
M.Wt:	922.803000000001
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Nemifitide diTFA (INN 00835 diTFA) is a synthetic pentapeptide antidepressant with a potential for rapid onset of action[1]. Nemifitide diTFA is a peptide analog of melanocyte-inhibiting factor (MIF)[2]. Nemifitide diTFA can cross the blood-brain barrier[3].
In Vivo:	Nemifitide diTFA (INN 00835 diTFA; 0.3 mg/kg; IP; daily; for 14 days) significantly increases swimming in the FSL rats after just 5 days of treatment and has long-lasting effect[2]. Nemifitide diTFA (0.0125-15.0 mg/kg) significantly increases swimming in the FSL rats at both low (0.025-0.3 mg/kg) and high (3.0-15.0 mg/kg) doses but not at intermediate (0.4-2.4 mg/kg) doses[2]. Animal Model: Male Flinders Sensitive Line (FSL) rat weighing 280-320 g[2] Dosage: 0.3 mg/kg Administration: IP; daily; for 14 days Result: Significantly increased swimming in the FSL rats after just 5 days of treatment and had long-lasting effect.
In Vitro:	Nemifitide diTFA (INN 00835 diTFA) and its active metabolite (M1) bind at micromolar concentrations to several receptors including the 5-HT2A, 5-HT2C, melanocortin MC4, MC5 and bombesin[3].
References:	[1]. Kelly JP, et al. The effect of treatment with a new antidepressant, INN 00835, on platelet serotonin uptake in depressed patients. J Affect Disord. 1999 Oct;55(2-3):231-5. [2]. Overstreet DH, et al. Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression. Psychopharmacology (Berl). 2004 Sep;175(3):303-9. [3]. Montgomery SA, et al. Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressivedisorder. Int J Neuropsychopharmacol. 2006 Oct;9(5):517-28.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.